LA JOLLA, Calif., September 2, 2025 – Enlaza Therapeutics, the first covalent biologics platform company, today announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals (Nasdaq: VRTX) to utilize Enlaza’s...
Bayhill Therapeutics enters exclusive, worldwide collaboration with Genentech for BHT-3021 in Type 1 diabetes
News | 06. 10. 2009
Bayhill Therapeutics
SAN MATEO, Calif.--(BUSINESS WIRE)--Bayhill Therapeutics Inc. announced today that it has entered into an exclusive worldwide license agreement for the development and potential commercialization of BHT-3021 with Genentech, Inc. a wholly-owned member of the Roche Group. BHT-3021 is Bayhill’s DNA based antigen specific immunotherapy currently in a phase I/II clinical trial in patients with type 1 diabetes (T1D).
